Improving Patient Recruitment in Biosimilar Trials


ISR believes we are in the beginning stages of high-growth for Biosimilars. Teva’s August, 2012 FDA approval for two of Amgen’s products (Neupogen & Neulasta) signals a milestone for the development of Biosimilars. It is interesting to note that Teva chose to use the Biologics License Application (BLA) process, normally reserved for novel products, as their route to approval. While this has both regulatory and commercial implications, the clinical development implications center on the fact that if others follow this route, the magnitude of the trials needed for a Biosimilar approval increase dramatically. With increased clinical trial activity through Phase III, the ability to recruit patients into these important studies will become a key stepping stone to Biosimilar commercial success.



  • Better understanding of how sites view Biosimilar trials today
  • Understand the current barriers to Biosimilar patient recruiting
  • Learn what the most successful techniques are for recruiting patients into Biosimilar studies
  • Craft patient-centric messaging that will resonate, provide a launching pad for discussions, and drive trial participation
  • Conceptualize how an integrated approach is needed between early pharma trial design, sponsor/ CRO assistance for sites in patient recruiting, and developing tools/ collateral/ language/ messages for site and patient recruitment
  1. Summary and Recommendations, including how pharma/CROs can motivate sites and how sites can motivate patients
  2. Biosimilar environment at the site
  3. Barriers to Biosimilar patient recruitment
  4. Recommendations for Biosimilar patient recruitment
  5. Study data, including patient recruitment trends, biosimilar recruiting, analysis by practice type, and respondent/ site demographics

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at

Additional information


, ,


There are no reviews yet.

Be the first to review “Improving Patient Recruitment in Biosimilar Trials”